
News|Events|August 7, 2026
FAQ: What mFLUSIVA's Approval May Signal for the Future of mRNA Vaccine Development
Author(s)Emily Schoenthaler
Moderna's mFLUSIVA approval offers a regulatory case study for mRNA vaccine sponsors, covering comparator selection lessons from the FDA's reversed refusal-to-file, competitive implications for Pfizer and Sanofi's mRNA flu programs, and what the accelerated approval pathway means for long-term regulatory risk.
Advertisement
Advertisement
Moderna's mFLUSIVA approval on August 5, 2026, marks a milestone for mRNA vaccine development, offering insight into regulatory considerations that may influence future mRNA vaccine submissions, including comparator selection, accelerated approval strategies, and clinical development planning.
Related to this article

Galinpepimut-S maintenance extended median overall survival to 24.0 vs 14.7 months in transplant-ineligible AML patients in second or later remission.

DISCO Pharmaceuticals will receive $40 million upfront, with up to $2.5 billion in potential milestones, to discover bispecific therapeutics for AbbVie that recognize pairs of tumor surface proteins, an approach intended to limit toxicity in healthy tissue.

Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.

Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.

Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.

FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.

J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, and Lilly agreed to buy Calytrix Bio for up to $1.5 billion. Novartis licensed OBI Pharma’s ADC platform, and Seawolf debuted with $100 million and a Sanofi pact.
Advertisement
Advertisement

